Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Oncology · J Natl Cancer Inst · 2026-11-01
RCTn = 278
Sharma et al. Concurrent chemotherapy and external radiation therapy (ConCERT): phase 3 noninferiority randomized clinical trial of cisplatin weekly vs every 3 weeks in locally advanced squamous cell carcinoma of the head and neckEar, nose and throat · Head Neck · 2026-10-05
Meta-analysisn = 1,044
Rahim et al. Efficacy and Safety of Cisplatin Versus Carboplatin for Patients With Squamous Cell Carcinoma of Head and Neck: A Systematic Review and Meta-AnalysisEar, nose and throat · Laryngoscope · 2026-07-29
Meta-analysisn = 4,395
Capriotti et al. Treatment of Locally Advanced Layngohypopharyngeal Cancers: A Network Meta-AnalysisOncology · J Clin Oncol · 2026-06-26
Clinical trialn = 261
Tahara et al. Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck CancerOncology · Lancet Oncol · 2026-06-15
RCTn = 624
Li et al. Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trialOncology · ESMO Open · 2026-03-19
RCTn = 150
Gong et al. A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancerOncology · ESMO Open · 2026-03-10
RCTn = 314 patients
Ryu et al. A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) studyGastroenterology · Lancet · 2025-11-20
RCTn = 260
Reni et al. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial